Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
29495 | 185 | 38.4 | 73% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
17 | 4 | REPRODUCTIVE BIOLOGY//OBSTETRICS & GYNECOLOGY//VETERINARY SCIENCES | 563730 |
256 | 3 | VETERINARY SCIENCES//DOG//JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION | 44961 |
3360 | 2 | PTERIDIUM AQUILINUM//BRACKEN//EQUINE SARCOID | 1696 |
29495 | 1 | IROFULVEN//ILLUDINS//MGI 114 | 185 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | IROFULVEN | authKW | 4694934 | 17% | 89% | 32 |
2 | ILLUDINS | authKW | 3760185 | 15% | 84% | 27 |
3 | MGI 114 | authKW | 2979268 | 10% | 95% | 19 |
4 | HMAF | authKW | 2156737 | 8% | 93% | 14 |
5 | 6 HYDROXYMETHYLACYLFULVENE | authKW | 1320452 | 4% | 100% | 8 |
6 | ACYLFULVENE | authKW | 1320452 | 4% | 100% | 8 |
7 | ALKENAL ONE OXIDOREDUCTASE | authKW | 330113 | 1% | 100% | 2 |
8 | DIFFERENTIAL APOPTOSIS | authKW | 330113 | 1% | 100% | 2 |
9 | HYDROXYMETHYLACYLFULVENE | authKW | 330113 | 1% | 100% | 2 |
10 | ILLUDIN M | authKW | 330113 | 1% | 100% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 1113 | 41% | 0% | 75 |
2 | Pharmacology & Pharmacy | 495 | 31% | 0% | 58 |
3 | Chemistry, Medicinal | 451 | 15% | 0% | 28 |
4 | Chemistry, Organic | 147 | 14% | 0% | 26 |
5 | Toxicology | 132 | 9% | 0% | 16 |
6 | Mycology | 24 | 2% | 0% | 3 |
7 | Plant Sciences | 14 | 5% | 0% | 10 |
8 | Chemistry, Multidisciplinary | 13 | 9% | 0% | 16 |
9 | Biochemistry & Molecular Biology | 9 | 11% | 0% | 20 |
10 | Hematology | 3 | 2% | 0% | 4 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PATHOL 8320 | 330113 | 1% | 100% | 2 |
2 | CORE IL PROTE STRUCT BIOL | 165057 | 1% | 100% | 1 |
3 | DR JACQUES POUYSSEGUR | 165057 | 1% | 100% | 1 |
4 | GENITOURY ONCOL SERV | 165057 | 1% | 100% | 1 |
5 | MAY BABB RANDOLPH CANC | 165057 | 1% | 100% | 1 |
6 | NORDAN COLON DRUG DEV | 165057 | 1% | 100% | 1 |
7 | SIGNAL TRANSDUCT CELLULAR FUNCT DIABET DI | 165057 | 1% | 100% | 1 |
8 | UNITE 524 INSERM | 165057 | 1% | 100% | 1 |
9 | GRP BIOL PHARMACOGENET HUMAN TUMORS | 132043 | 1% | 40% | 2 |
10 | CANC CELL BIOL BRANCH | 110035 | 1% | 33% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INVESTIGATIONAL NEW DRUGS | 7819 | 6% | 0% | 11 |
2 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2713 | 6% | 0% | 11 |
3 | CHEMICAL RESEARCH IN TOXICOLOGY | 1135 | 3% | 0% | 6 |
4 | METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 1008 | 2% | 0% | 4 |
5 | ANTI-CANCER DRUGS | 803 | 2% | 0% | 4 |
6 | XENOBIOTICA | 676 | 2% | 0% | 4 |
7 | JOURNAL OF NATURAL PRODUCTS | 487 | 3% | 0% | 6 |
8 | BIOCHEMICAL PHARMACOLOGY | 428 | 4% | 0% | 7 |
9 | CLINICAL CANCER RESEARCH | 392 | 3% | 0% | 6 |
10 | AUSTRALIAN JOURNAL OF CROP SCIENCE | 370 | 1% | 0% | 1 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IROFULVEN | 4694934 | 17% | 89% | 32 | Search IROFULVEN | Search IROFULVEN |
2 | ILLUDINS | 3760185 | 15% | 84% | 27 | Search ILLUDINS | Search ILLUDINS |
3 | MGI 114 | 2979268 | 10% | 95% | 19 | Search MGI+114 | Search MGI+114 |
4 | HMAF | 2156737 | 8% | 93% | 14 | Search HMAF | Search HMAF |
5 | 6 HYDROXYMETHYLACYLFULVENE | 1320452 | 4% | 100% | 8 | Search 6+HYDROXYMETHYLACYLFULVENE | Search 6+HYDROXYMETHYLACYLFULVENE |
6 | ACYLFULVENE | 1320452 | 4% | 100% | 8 | Search ACYLFULVENE | Search ACYLFULVENE |
7 | ALKENAL ONE OXIDOREDUCTASE | 330113 | 1% | 100% | 2 | Search ALKENAL+ONE+OXIDOREDUCTASE | Search ALKENAL+ONE+OXIDOREDUCTASE |
8 | DIFFERENTIAL APOPTOSIS | 330113 | 1% | 100% | 2 | Search DIFFERENTIAL+APOPTOSIS | Search DIFFERENTIAL+APOPTOSIS |
9 | HYDROXYMETHYLACYLFULVENE | 330113 | 1% | 100% | 2 | Search HYDROXYMETHYLACYLFULVENE | Search HYDROXYMETHYLACYLFULVENE |
10 | ILLUDIN M | 330113 | 1% | 100% | 2 | Search ILLUDIN+M | Search ILLUDIN+M |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SCHOBERT, R , KNAUER, S , SEIBT, S , BIERSACK, B , (2011) ANTICANCER ACTIVE ILLUDINS: RECENT DEVELOPMENTS OF A POTENT ALKYLATING COMPOUND CLASS.CURRENT MEDICINAL CHEMISTRY. VOL. 18. ISSUE 6. P. 790 -807 | 61 | 80% | 20 |
2 | TANASOVA, M , STURLA, SJ , (2012) CHEMISTRY AND BIOLOGY OF ACYLFULVENES: SESQUITERPENE-DERIVED ANTITUMOR AGENTS.CHEMICAL REVIEWS. VOL. 112. ISSUE 6. P. 3578-3610 | 89 | 40% | 14 |
3 | KELNER, MJ , MCMORRIS, TC , ROJAS, RJ , ESTES, LA , SUTHIPINIJTHAM, P , (2008) SYNERGY OF IROFULVEN IN COMBINATION WITH VARIOUS ANTI-METABOLITES, ENZYME INHIBITORS, AND MISCELLANEOUS AGENTS IN MV522 LUNG CARCINOMA CELLS: MARKED INTERACTION WITH GEMCITABINE AND 5-FLUOROURACIL.INVESTIGATIONAL NEW DRUGS. VOL. 26. ISSUE 5. P. 407 -415 | 40 | 71% | 5 |
4 | BOMGAARS, LR , MEGASON, GC , PULLEN, J , LANGEVIN, AM , WEITMAN, SD , HERSHON, L , KUHN, JG , BERNSTEIN, M , BLANEY, SM , (2006) PHASE I TRIAL OF IROFULVEN (MGI 114) IN PEDIATRIC PATIENTS WITH SOLID TUMORS.PEDIATRIC BLOOD & CANCER. VOL. 47. ISSUE 2. P. 163-168 | 27 | 100% | 2 |
5 | KELNER, MJ , MCMORRIS, TC , ROJAS, RJ , ESTES, LA , SUTHIPINIJTHAM, P , (2008) SYNERGY OF IROFULVEN IN COMBINATION WITH OTHER DNA DAMAGING AGENTS: SYNERGISTIC INTERACTION WITH ALTRETAMINE, ALKYLATING, AND PLATINUM-DERIVED AGENTS IN THE MV522 LUNG TUMOR MODEL.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 63. ISSUE 1. P. 19 -26 | 27 | 75% | 8 |
6 | MCMORRIS, TC , YU, J , LIRA, R , DAWE, R , MACDONALD, JR , WATERS, SJ , ESTES, LA , KELNER, MJ , (2001) STRUCTURE-ACTIVITY STUDIES OF ANTITUMOR AGENT IROFULVEN (HYDROXYMETHYLACYLFULVENE) AND ANALOGUES.JOURNAL OF ORGANIC CHEMISTRY. VOL. 66. ISSUE 18. P. 6158-6163 | 24 | 96% | 18 |
7 | PIETSCH, KE , VAN MIDWOUD, PM , VILLALTA, PW , STURLA, SJ , (2013) QUANTIFICATION OF ACYLFULVENE- AND ILLUDIN S-DNA ADDUCTS IN CELLS WITH VARIABLE BIOACTIVATION CAPACITIES.CHEMICAL RESEARCH IN TOXICOLOGY. VOL. 26. ISSUE 1. P. 146-155 | 21 | 75% | 3 |
8 | GLATT, H , PIETSCH, KE , STURLA, SJ , MEINL, W , (2014) SULFOTRANSFERASE-INDEPENDENT GENOTOXICITY OF ILLUDIN S AND ITS ACYLFULVENE DERIVATIVES IN BACTERIAL AND MAMMALIAN CELLS.ARCHIVES OF TOXICOLOGY. VOL. 88. ISSUE 1. P. 161-169 | 24 | 65% | 0 |
9 | KELNER, MJ , MCMORRIS, TC , ROJAS, RJ , TRANI, NA , VELASCO, TR , ESTES, LA , SUTHIPINIJTHAM, P , (2002) ENHANCED ANTITUMOR ACTIVITY OF IROFULVEN IN COMBINATION WITH ANTIMITOTIC AGENTS.INVESTIGATIONAL NEW DRUGS. VOL. 20. ISSUE 3. P. 271-279 | 21 | 84% | 13 |
10 | WOO, MH , PETERSON, JK , BILLUPS, C , LIANG, H , BJORNSTI, MA , HOUGHTON, PJ , (2005) ENHANCED ANTITUMOR ACTIVITY OF IROFULVEN IN COMBINATION WITH IRINOTECAN IN PEDIATRIC SOLID TUMOR XENOGRAFT MODELS.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 55. ISSUE 5. P. 411 -419 | 21 | 72% | 17 |
Classes with closest relation at Level 1 |